- Nghiên cứu có thể được phát triển theo hướng đánh giá can thiệp của DSLS trong tối ưu hóa hiệu quả – chi phí điều trị;
- Mô hình nghiên cứu có thiết kế chặt chẽ hơn để đánh giá toàn diện hơn việc chỉnh liều của DSLS, thời điểm lấy mẫu máu của điều dưỡng và hiệu quả thực sự sau khi xuống thang kháng sinh;
- Nghiên cứu có thể được mở rộng trên đối tượng trẻ em, bệnh nhân thực hiện liệu pháp thay thế thận hoặc các nhóm đối tượng thuộc tiêu chuẩn loại trừ của nghiên cứu.
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
69
TÀI LIỆU THAM KHẢO
1. van Hal S.J., Paterson D.L., Lodise T.P. (2013), "Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter",
Antimicrob Agents Chemother,57(2):734-744.
2. Sinha Ray A., Haikal A., Hammoud K.A., et al. (2016), "Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis", Clin J Am Soc Nephrol,11(12):2132-2140.
3. Alvarez R., Lopez Cortes L.E., Molina J., et al. (2016), "Optimizing the Clinical Use of Vancomycin", Antimicrob Agents Chemother, 60(5):2601- 2609.
4. Hirano R., Sakamoto Y., Kitazawa J., et al. (2016), "Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus
infections: a single institution experience", Infect Drug Resist,9:243-252. 5. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. (2009), "Therapeutic
monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists", Pharmacotherapy,29(11):1275-1279.
6. Liu C., Bayer A., Cosgrove S.E., et al. (2011), "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children", Clin Infect Dis,52(3):285-292.
7. Matsumoto K., Takesue Y., Ohmagari N., et al. (2013), "Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring", J Infect Chemother, 19(3):365-380.
8. VA Greater Los Angeles Healthcare System (2013), "Vancomycin Dosing and Monitoring of Serum Vancomycin Levels Infectious Diseases Section Guidelines".
9. Rybak M.J., Le J., Lodise T.P., et al. (2020), "Therapeutic Monitoring of Vancomycin for serious methicillin-resistant Staphylococcus aureus
Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists", Clinical Infectious Diseases.
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
70
10. Trần Ngọc Phương Minh, Đặng Nguyễn Đoan Trang (2019), "Khảo sát và đánh giá hiệu quả theo dõi nồng độ vancomycin trong trị liệu tại bệnh viện Đại học Y Dược thành phố Hồ Chí Minh", Nghiên cứu Dược và Thông tin thuốc,10(3):30-37.
11. Davis S.L., Scheetz M.H., Bosso J.A., et al. (2013), "Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals", Pharmacotherapy, 33(12):1256- 1263.
12. ASHP (2010), "ASHP statement on the Pharmacist’s Role in Antimicrobial Stewardship and Infection Prevention and Control", American Journal of Health-System Pharmacy,67:575-577.
13. Bộ Y tế (2016), "Hướng dẫn thực hiện quản lý sử dụng kháng sinh trong bệnh viện". Quyết định 722/QĐ-BYT. Cập nhật: 04/03/2016.
14. Xu G., Chen E., Mao E., et al. (2018), "[Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data]", Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,30(7):640-645.
15. MacDougall C. (2018) Chapter 59: Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents. IN Brunton L.L., Hilal-Dandan R., Knollmann B.C. (Eds.) Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13 ed. McGraw-Hill Education, New York, NY, pp. 1050- 1064.
16. Bennett J.E., Dolin R., Blaser M.J. (2020), "Mandell, Douglas, and Bennett's principles and practice of infectious diseases".
17. DrugBank, "Vancomycin", [database online].
https://www.drugbank.ca/drugs/DB00512. Truy cập: 12/12/2019
18. Dasgupta A. (2012), "Advances in antibiotic measurement. Advances in Clinical Chemistry", 56:75–104.
19. National Center for Biotechnology Information. PubChem Database
"Vancomycin, CID=14969".
https://pubchem.ncbi.nlm.nih.gov/compound/Vancomycin. Truy cập:
12/12/2019.
20. FDA (2003), "Vancomycin Hydrochloride Capsuless, USP".
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50606slr020_va
ncocin_lbl.pdf. Truy cập: 12/12/2019.
21. Patel S., Preuss C.V., Bernice F. (2020), "Vancomycin". StatPearls.
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
71
22. Wood A., Wassil K., Edwards E. (2013), "Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment", J Pediatr Pharmacol Ther,18(4):315-317.
23. Aradhyula S., Manian F.A., Hafidh S.A., et al. (2006), "Significant absorption of oral vancomycin in a patient with clostridium difficile colitis and normal renal function", South Med J, 99(5):518-520.
24. FDA (2018), "Drug Approval Package: Vancomycin Hydrochloride".
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209481Orig1s000
Lbl.pdf. Truy cập: 12/12/2019.
25. Rybak M.J. (2006), "The pharmacokinetic and pharmacodynamic properties of vancomycin", Clin Infect Dis,42 Suppl 1:S35-39.
26. Ricard J.D., Wolff M., Lacherade J.C., et al. (2007), "Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study", Clin Infect Dis,44(2):250-255.
27. Ishikawa M., Yamazaki S., Suzuki T., et al. (2019), "Correlation between vancomycin penetration into cerebrospinal fluid and protein concentration in cerebrospinal fluid/serum albumin ratio", J Infect Chemother,25(2):124-128. 28. Skhirtladze K., Hutschala D., Fleck T., et al. (2006), "Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery",
Antimicrob Agents Chemother,50(4):1372-1375.
29. Cao M., Feng Y., Zhang Y., et al. (2018), "Studies on the metabolism and degradation of vancomycin in simulated in vitro and aquatic environment by UHPLC-Triple-TOF-MS/MS", Scientific Reports,8(1):15471.
30. Vandecasteele S.J., De Vriese A.S. (2010), "Recent changes in vancomycin use in renal failure", Kidney Int,77(9):760-764.
31. Bauer L.A. (2015) Vancomycin. Applied Clinical Pharmacokinetics, 3e.
McGraw-Hill Medical,New York, NY.
32. Brunetti L., Song J.H., Suh D., et al. (2020), "The risk of vancomycin toxicity in patients with liver impairment", Ann Clin Microbiol Antimicrob,
19(1):13.
33. Katip W., Jaruratanasirikul S., Pattharachayakul S., et al. (2016), "The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock", Infect Drug Resist,9:253-260.
34. Ghosh N., Chavada R., Maley M., et al. (2014), "Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia",
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
72
Society of Clinical Microbiology and Infectious Diseases, 20(12):O1098- 1105.
35. Wayne P.a.L.S.I. (2007), Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement, 17th informational supplement, Clinical and Laboratory Standards Institute.
36. Mohr J.F., Murray B.E. (2007), "Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus", Clin Infect Dis,44(12):1536-1542.
37. "Vancomycin", Lexicomp [database online]. Hudson, OH: Wolters Kluwer, Inc; 2019. http://online.lexi.com. Truy cập: 12/12/2019.
38. Rybak M., J. L., Lodise T., et al. (2019), "Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases ", Am J Health-Syst Phar.
39. Kalil A.C., Metersky M.L., Klompas M., et al. (2016), "Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clinical Infectious Diseases,63(5):e61- e111.
40. David N.G., George M.E., Henry F.C., et al. (2019), The Sanford guide to antimicrobial therapy 2019, Sperryville, VA, USA : Antimicrobial Therapy, Inc.,
41. Cockcroft DW, Gault MH (1976), "Prediction of creatine clearance from serum creatinine", Nephron,16(1):31-41.
42. Nottingham University Hospitals "Guideline for antimicrobial dosing for
adults with renal impairment".
https://www.nuh.nhs.uk/download.cfm?doc=docm93jijm4n629.pdf&ver=47 73. Truy cập: 12/12/2019.
43. Winter MA G.K., Berg GM (2012), "Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the CockcroftGault equation", Pharmacotherapy,32:604-612.
44. Salazar D.E., Corcoran G.B. (1988), "Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass",
The American journal of medicine,84(6):1053-1060.
45. Panos G., Watson D.C., Sargianou M., et al. (2012), "Red Man Syndrome Adverse Reaction following Intravenous Infusion of Cefepime",
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
73
46. Singbartl K., Kellum J.A. (2012), "AKI in the ICU: definition, epidemiology, risk stratification, and outcomes", Kidney Int,81(9):819-825.
47. Linder A., Fjell C., Levin A., et al. (2014), "Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill", Am J Respir Crit Care Med,189(9):1075-1081.
48. Neely M.N., Kato L., Youn G., et al. (2018), "Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing", Antimicrob Agents Chemother,62(2). 49. Tong S.Y.C., Lye D.C., Yahav D., et al. (2020), "Effect of Vancomycin or
Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial", Jama,323(6):527-537.
50. Moenster R.P., Linneman T.W., Finnegan P.M., et al. (2014), "Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime", Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
20(6):O384-389.
51. Kadomura S., Takekuma Y., Sato Y., et al. (2019), "Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study", J Pharm Health Care Sci,5:13.
52. Filippone E.J., Kraft W.K., Farber J.L. (2017), "The Nephrotoxicity of Vancomycin", Clin Pharmacol Ther,102(3):459-469.
53. Filippone E.J., Kraft W.K., Farber J.L. (2017), "The Nephrotoxicity of Vancomycin", Clin Pharmacol Ther,102(3):459-469.
54. "Vancomycin Hydrochloride ", IBM Micromedex IV Compatibility [database online]. Greenwood Village, CO: IBM Watson Health information.
http://www.micromedexsolutions.com. Cập nhật: 12/12/2019. Truy cập:
12/12/2019.
55. Ye Z.K., Chen Y.L., Chen K., et al. (2016), "Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society", J Antimicrob Chemother, 71(11):3020- 3025.
56. Delyth A., Robert J. (2017), "Policy for the use of pulsed dose intravenous vancomycin in Adults". https://www.gloshospitals.nhs.uk/gps/antimicrobial- resources/a-z-bugs-and-drugs/vancomycin-dose-adjustment-renal-
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
74
57. Patel N., Pai M.P., Rodvold K.A., et al. (2011), "Vancomycin: We Can't Get There From Here", Clinical Infectious Diseases,52(8):969-974.
58. Neely M.N., Youn G., Jones B., et al. (2014), "Are vancomycin trough concentrations adequate for optimal dosing?", Antimicrob Agents Chemother,58(1):309-316.
59. Ye Z.K., Li C., Zhai S.D. (2014), "Guidelines for therapeutic drug monitoring of vancomycin: a systematic review", PLoS One,9(6):e99044. 60. Smith A.P., Millares-Sipin C.A., James M., et al. (2016), "Impact of a
Pharmacist-Initiated Vancomycin Monitoring Program", Consult Pharm,
31(9):505-510.
61. Marquis K.A., DeGrado J.R., Labonville S., et al. (2015), "Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center", Ann Pharmacother,49(9):1009-1014. 62. Momattin H., Zogheib M., Homoud A., et al. (2016), "Safety and Outcome
of Pharmacy-Led Vancomycin Dosing and Monitoring", Chemotherapy,
61(1):3-7.
63. Masuda N., Maiguma T., Komoto A., et al. (2015), "Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin", Int J Clin Pharmacol Ther,53(4):284-291.
64. Patel S., Brunetti L., Segal R., et al. (2013), "Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a Community Medical Center", Poster Abstract Session: Stewardship: Implementing Programs, ID week, San Francisco.
65. Luxenburg J., Sims S., Roesel M., et al. (2012), "Hitting the Target: Outcomes of a Pharmacy-Managed Vancomycin Dosing and Monitoring Strategy at a Tertiary-Care VA Medical Center", Poster Abstract Session: Antibiotic Stewardship: Theory and Practice, ID week, San Diego.
66. Nguyễn Thị Mai Anh, Nguyễn Hoàng Anh, Vũ Đình Hòa (2020), "Phân tích thực trạng sử dụng vancomycin ở bệnh nhân điều trị tại Khoa Hồi sức tích cực, Bệnh viện Thanh Nhàn", Tạp chí Dược học, (528):10-14.
67. Lê Vân Anh, Hoàng Thị Kim Huyền, Nguyễn Liên Hương (2013), "Đánh giá khả năng đạt AUC0-24/MIC mục tiêu của vancomycin trên bệnh nhân nhiếm tụ cầu vàng tại bệnh viện Bạch Mai", Y học thực hành,10(884):91-94.
68. Ahmadi E., Khojasteh M., Mortazavi S.M., et al. (2019), "Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus nasal carriage in the West of Iran: a population-based cross-sectional study", BMC Infect Dis,
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
75
69. Alhameed A.F., Khansa S.A., Hasan H., et al. (2019), "Bridging the Gap between Theory and Practice; the Active Role of Inpatient Pharmacists in Therapeutic Drug Monitoring", Pharmacy (Basel, Switzerland),7(1).
70. Phillips C.J., Gordon D.L. (2015), "Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes", Integr Pharm Res Pract,4:145-152.
71. Wong J.W., Ip M., Tang A., et al. (2018), "Prevalence and risk factors of community-associated methicillin-resistant Staphylococcus aureus carriage in Asia-Pacific region from 2000 to 2016: a systematic review and meta- analysis", Clin Epidemiol, 10:1489-1501.
72. Rybak M.J., Vidaillac C., Sader H.S., et al. (2013), "Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods", J Clin Microbiol,51(7):2077-2081.
73. Dilworth T.J., Ibrahim O., Hall P., et al. (2014), "β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus
bacteremia compared to vancomycin alone", Antimicrob Agents Chemother,
58(1):102-109.
74. Zheng X., Berti A.D., McCrone S., et al. (2018), "Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus", Antimicrob Agents Chemother,62(2). 75. Wargo K.A., McCreary E.K., English T.M. (2015), "Vancomycin Combined
With Clindamycin for the Treatment of Acute Bacterial Skin and Skin- Structure Infections", Clin Infect Dis,61(7):1148-1154.
76. Hanrahan T.P., Kotapati C., Roberts M.J., et al. (2015), "Factors associated with vancomycin nephrotoxicity in the critically ill", Anaesth Intensive Care,
43(5):594-599.
77. Jensen J.U., Hein L., Lundgren B., et al. (2012), "Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial", BMJ Open,2(2):e000635. 78. Giuliano C.A., Patel C.R., Kale-Pradhan P.B. (2016), "Is the Combination of
Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis", Pharmacotherapy, 36(12):1217- 1228.
79. Hammond D.A., Smith M.N., Li C., et al. (2017), "Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam", Clin Infect Dis,64(5):666-674.
Đề cương khóa luận tốt nghiệp DSĐH Tài liệu tham khảo
76
80. Suzuki Y., Kawasaki K., Sato Y., et al. (2012), "Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic- pharmacodynamic analysis in patients with methicillin-resistant
Staphylococcus aureus pneumonia", Chemotherapy,58(4):308-312.
81. Nakashima T., Koido K., Baba H., et al. (2018), "Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing", Pharmazie, 73(7):422-424.
82. Willis C., Allen B., Tucker C., et al. (2017), "Impact of a pharmacist-driven methicillin-resistant Staphylococcus aureus surveillance protocol", Am J Health Syst Pharm,74(21):1765-1773.
83. Cardile A.P., Tan C., Lustik M.B., et al. (2015), "Optimization of time to initial vancomycin target trough improves clinical outcomes", Springerplus,
4:364.
84. Mullins B.P., Kramer C.J., Bartel B.J., et al. (2018), "Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study", Ann Pharmacother,52(7):639-644.
85. Rutter W.C., Cox J.N., Martin C.A., et al. (2017), "Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime", Antimicrob Agents Chemother,61(2).
86. Cano E.L., Haque N.Z., Welch V.L., et al. (2012), "Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database", Clin Ther,34(1):149-157.
87. Hanrahan T.P., Harlow G., Hutchinson J., et al. (2014), "Vancomycin- associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*", Crit Care Med,42(12):2527-2536.
Đề cương khóa luận tốt nghiệp DSĐH Phụ lục
PL.1
PHỤ LỤC
Phụ lục 1: Hướng dẫn sử dụng và TDM của vancomycin Phụ lục 2: Các thang điểm được sử dụng trong nghiên cứu Phụ lục 3: Mẫu thu thập số liệu TDM của vancomycin
Phụ lục 1: Hướng dẫn sử dụng và TDM của vancomycin tại bệnh viện Đại Y Dược thành phố Hồ Chí Minh
A. Liều nạp vancomycin
1. Sử dụng liều nạp ở các đối tượng nhiễm khuẩn nặng hoặc đe dọa tính mạng bao gồm:
▪ Nhiễm khuẩn huyết ▪ Viêm phổi
▪ Viêm nội tâm mạc nhiễm khuẩn ▪ Viêm khớp nhiễm khuẩn
▪ Viêm tủy xương ▪ Viêm màng não
2. Liều nạp khuyến cáo 25 – 30 mg/kg (cân nặng thực tế)